Literature DB >> 21245096

LATS2 is a tumor suppressor gene of malignant mesothelioma.

Hideki Murakami1, Tetsuya Mizuno, Tetsuo Taniguchi, Makiko Fujii, Futoshi Ishiguro, Takayuki Fukui, Shinya Akatsuka, Yoshitsugu Horio, Toyoaki Hida, Yutaka Kondo, Shinya Toyokuni, Hirotaka Osada, Yoshitaka Sekido.   

Abstract

Malignant mesothelioma (MM) is an aggressive neoplasm associated with asbestos exposure. We carried out genome-wide array-based comparative genomic hybridization analysis with 14 MM cell lines. Three cell lines showed overlapping homozygous deletion at chromosome 13q12, which harbored the LATS2 (large tumor suppressor homolog 2) gene. With 6 other MM cell lines and 25 MM tumors, we found 10 inactivating homozygous deletions or mutations of LATS2 among 45 MMs. LATS2 encodes a serine/threonine kinase, a component of the Hippo tumor-suppressive signaling pathway, and we transduced LATS2 in MM cells with its mutation. Transduction of LATS2 inactivated oncoprotein YAP, a transcriptional coactivator, via phosphorylation, and inhibited MM cell growth. We also analyzed LATS2 immunohistochemically and found that 13 of 45 MM tumors had low expression of LATS2. Because NF2 is genetically mutated in 40% to 50% of MM, our data indicate that Hippo pathway dysregulation is frequent in MM cells with inactivation of LATS2 or an upstream regulator of this pathway, Merlin, which is encoded by NF2. Thus, our results suggest that the inactivation of LATS2 is one of the key mechanisms for constitutive activation of YAP, which induces deregulation of MM cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245096     DOI: 10.1158/0008-5472.CAN-10-2164

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  97 in total

Review 1.  The Hippo pathway regulates stem cell proliferation, self-renewal, and differentiation.

Authors:  Huan Liu; Dandan Jiang; Fangtao Chi; Bin Zhao
Journal:  Protein Cell       Date:  2012-05-02       Impact factor: 14.870

Review 2.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

Review 3.  Drug development against the hippo pathway in mesothelioma.

Authors:  Gavitt A Woodard; Yi-Lin Yang; Liang You; David M Jablons
Journal:  Transl Lung Cancer Res       Date:  2017-06

4.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

5.  Important recent insights into the genetics and biology of malignant pleural mesothelioma.

Authors:  Robert McMillan; Marjorie Zauderer; Matthew Bott; Marc Ladanyi
Journal:  Ann Cardiothorac Surg       Date:  2012-11

6.  The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.

Authors:  Lin Zhang; Shuping Yang; Xingcheng Chen; Seth Stauffer; Fang Yu; Subodh M Lele; Kai Fu; Kaustubh Datta; Nicholas Palermo; Yuanhong Chen; Jixin Dong
Journal:  Mol Cell Biol       Date:  2015-02-02       Impact factor: 4.272

7.  Long Noncoding RNA LINC00673 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with LSD1 and EZH2 in Gastric Cancer.

Authors:  Mingde Huang; Jiakai Hou; Yunfei Wang; Min Xie; Chenchen Wei; Fengqi Nie; Zhaoxia Wang; Ming Sun
Journal:  Mol Ther       Date:  2017-02-15       Impact factor: 11.454

Review 8.  MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets.

Authors:  Glen Reid
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

9.  Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.

Authors:  Ana Sebio; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

Review 10.  The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Authors:  Xiao-Lan Liu; Rui Zuo; Wen-Bin Ou
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.